MedPath

Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: IC83/LY2603618
Drug: pemetrexed
First Posted Date
2006-12-25
Last Posted Date
2018-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
31
Registration Number
NCT00415636
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
First Posted Date
2006-12-22
Last Posted Date
2010-08-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
53
Registration Number
NCT00415168
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation

Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
Small Cell Lung Cancer
Interventions
Drug: placebo
Drug: enzastaurin
First Posted Date
2006-12-22
Last Posted Date
2020-11-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
109
Registration Number
NCT00415363
Locations
🇸🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden

A Study for Patients With Head and Neck Cancer

Phase 3
Completed
Conditions
Head and Neck Neoplasms
Interventions
First Posted Date
2006-12-22
Last Posted Date
2011-06-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
795
Registration Number
NCT00415194
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

A Study for Patients With Osteoporosis

Phase 3
Completed
Conditions
Osteoporosis
Interventions
First Posted Date
2006-12-22
Last Posted Date
2009-10-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
364
Registration Number
NCT00414973
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wenzhou, China

A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

Phase 1
Withdrawn
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2006-12-22
Last Posted Date
2008-08-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
60
Registration Number
NCT00415155
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain

A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Drug: Placebo
Drug: Enzastaurin
First Posted Date
2006-12-22
Last Posted Date
2020-09-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
40
Registration Number
NCT00414960
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States

Evaluation of the Effects of Duloxetine on Norepinephrine

Phase 1
Completed
Conditions
Major Depressive Disorder
First Posted Date
2006-12-21
Last Posted Date
2007-06-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
35
Registration Number
NCT00414323
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2006-12-08
Last Posted Date
2010-09-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
70
Registration Number
NCT00409006
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China

Phase 3
Completed
Conditions
Diabetic Neuropathies
Interventions
First Posted Date
2006-12-08
Last Posted Date
2011-07-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
215
Registration Number
NCT00408993
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China

© Copyright 2025. All Rights Reserved by MedPath